<DOC>
	<DOC>NCT00943592</DOC>
	<brief_summary>This is a clinical research study designed to evaluate whether a conditioning regimen consisting of the combination of three drugs named melphalan, alemtuzumab and clofarabine supported by donor blood cells will result in rapid recovery and a high rate of long-lasting remissions in patients with leukemia, lymphoma and myeloma.</brief_summary>
	<brief_title>Clofarabine-Melphalan-Alemtuzumab Conditioning in Patients With Advanced Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Relapsed or refractory acute myelogenous or lymphoid leukemia Chronic myelogenous leukemia in accelerated phase or blastcrisis Chronic myelogenous leukemia in second or subsequent chronic phase Recurrent or refractory malignant lymphoma or Hodgkin's disease Multiple myeloma at high risk for disease recurrence Chronic lymphocytic leukemia, relapsed or with poor prognostic features Other Myeloproliferative disorder (polycythemia vera, essential thrombocythemia, myelofibrosis) with poor prognostic features Myelodysplastic syndromes (including PNH) with &gt; 5% blasts Zubroid performance status &lt; 2 (See Appendix B) Life expectancy is not severely limited by concomitant illness Adequate cardiac and pulmonary function. Patients with decreased LVEF or PFTS will be evaluated by cardiology or pulmonary prior to enrollment on this protocol Calculated Creatinine Clearance &gt; 50 ml/min Serum bilirubin 2.0 mg/dl, SGPT &lt; 3x upper limit of normal No evidence of chronic active hepatitis or cirrhosis HIVnegative Patient is not pregnant Patient or guardian able to sign informed consent Clinical progression</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Melphalan</keyword>
	<keyword>Alemtuzumab</keyword>
	<keyword>Clofarabine</keyword>
</DOC>